Primary systemic chemotherapy which forms the prime modality in LABC management has several advantages.
INTRODUCTION
Locally advanced breast cancer (LABC) refers to a heterogeneous group of locally advanced non metastatic group of breast cancer. It includes clinically advanced primary tumour (T4 disease including inflammatory carcinomas) and advanced nodal disease (N2 & N3 disease). Clinical stage 111A, 111B & 111C of AJCC staging system for Breast cancer represents the clinical spectrum of LABC. 1 The paradigm shift in the understanding of tumour biology has brought out several changes in management of breast cancer. Optimal management of LABC is complex. Primary Systemic chemotherapy (PST) otherwise called neoadjuvant chemotherapy (NACT) followed by local treatment in the form of surgery & radiation treatment and thereafter adjuvant systemic chemotherapy has become the standard of care for LABC.
It helps in reduction of tumour volume thereby down staging the disease. It increases the rate of radical surgery and even makes breast conservation surgery a possible thing in LABC. In addition to better control of local disease it takes care of the distant undetectable microscopic disease. Response to PST serves as a marker for long term outcome and may even help the clinician to change the chemotherapeutic agent if it appears resistant. The disadvantage is that it results in loss of assessment of well documented pathologic prognostic markers like initial tumour size, axillary lymph node involvement etc.; due to the pathological response to PST. 2, 3 Thus for inoperable disease, the initial approach should be PST with the aim of achieving resectability. For operable LABC, the survival rates are equivalent for both PST and adjuvant chemotherapy if same regimen is used even in different sequence making PST a viable option. [4] [5] [6] [7] Most commonly used PST regimen is anthracycline containing combination chemotherapy. There is enough evidence to show the benefit from Anthracycline combination chemotherapy. [8] [9] [10] [11] [12] Data from RCTs show that the rate of breast conserving surgery and pathologic complete response was significantly higher for patients receiving taxanes (Docetaxel). [13] [14] [15] [16] [17] [18] [19] No consensus exists whether anthracycline and taxanes can be used in combination or in sequence.
In western countries the incidence of LABC has proportionately decreased with more use of screening mammography whereas in Indian sub-continent cases are very high. LABC is a daily challenge for surgeons and oncologists of low resources countries due to the increased incidence. [20] [21] [22] [23] Data from various cancer registries in India reveal that the percentage advanced breast cancer patients (stage 111 & 1V together) is 50-70%. But studies on LABC are less among Indian population. Hence through this study we have tried to assess the role and adequacy of Anthracycline combination PST in down staging the disease in Indian patients. We also investigated the survival of these patients and comparing the same with existing international data.
METHODS

Patient selection
Women with primarily inoperable LABC satisfying all the following inclusion criteria were eligible for the study. Patients were excluded from the study if they were detected to have the following: Cardiology evaluation includes detailed history taking, clinical examination, ECG evaluation and Echocardiogram to assess the left ventricular ejection fraction (LVEF). Patients with less than 50% LVEF were excluded. Patients were also taken up for a preanaesthetic check-up to rule out any medical contraindication for surgery. If any contraindication for surgery then they were excluded from the study. and Cyclophosphamide 500 mg/m2 given on single day intravenously. On the start of chemotherapy the tumor size were measured as two largest perpendicular diameters. Thereafter the tumor response and operability were assessed during each visit for chemotherapy.
Chemotherapy was given at 21 days interval if the haematological parameters were adequate. Chemotherapy was postponed to a maximum of 1 week if bone marrow reserve was inadequate. Granulocyte colony stimulating factors and supportive treatment were given for febrile neutropenia wherever indicated. Haematological and non haematological toxicity was assessed based on NCI common toxicity criteria. Numbers of Primary systemic Chemotherapy cycles planned were 3-4. All patients after completion of three cycles were assessed by the surgeon for operability. If operable they were taken up for modified radical mastectomy with axillary clearance (MRM+AC). If inoperable then one more cycle will be given and reassessed for surgery. If still inoperable and stable or progressive disease then taxanes were tried. Thereafter if response is inadequate for a definitive surgery then those patients were taken for simple or toilet mastectomy or radical radiation treatment. All patients after radical surgical treatment were given adjuvant chemotherapy so that total of chemotherapy cycles is six.
As previously decided all radically treated patients were taken up for local radiation treatment to chest wall and drainage areas. Radiation treatment was given in a Telecobalt machine. A total dose of 50Gy as 25 fractions was given to chest wall as two tangential fields over a period of 5 weeks. Supraclavicular fossa & axilla were treated with 50Gy as 25 fractions over a period of 5 weeks as direct on field. All patients were given 6Gy in single fraction as posterior axillary boost at the end of the 25 fractions treatment. Endocrine responsive patient (ER or PR positive) were given Tamoxifen or aromatase inhibitors as per protocol for a period of 5 years. Patients were kept on regular 3-4 monthly follow up. Follow up evaluation consisted of clinical examination to rule out local and systemic recurrences, relevant investigations were done based on the clinical findings and history. Annual mammogram was done for all patients on follow up.
Evaluation of tumor response to primary systemic chemotherapy
Response to chemotherapy was assessed both clinically and pathologically. Final clinical assessment was done by physical examination at the end of primary systemic chemotherapy. Pathological response was done on the MRM+AC specimen.
Patients were categorized as follows. A) Microscopically no residual disease-pCR (pathological complete response) B) Clinically no palpable disease-cCR (clinical complete response) C) >50% response, clinically palpable disease-CPR (clinical partial response) D) <50% response to no response -SD (stable disease).
Statistical analysis
Analysis was carried out using SPSS software with the help of medical statistician. Overall survival was calculated from start of treatment to date of death. DFS was calculated from start of treatment to date of first local or systemic recurrence. DFS and O.S was calculated using Kaplan -Meier method. Table 1 . Disease characteristics-It is depicted in Table 2 . Mainly Left breast was affected with disease. Majority patients presented with T4 disease. Tumour Grade 2 or 3 diseases was observed in more than 96% of patients which points towards the high risk nature. With regard to the estrogen and progesterone receptor status there is high incidence of hormone negativity. Only one fourth of the patients were both ER/PR +ve. This is significantly lower than in white women. The total hormone receptor positivity was 43.2%.The high negativity may be due to the high disease stage and high grade of tumor. 
RESULTS
Preoperative chemotherapy (PST):
Routinely Anthracycline containing combination chemotherapy is given for locally advanced breast cancer in our institution. The most commonly used schedule is FAC followed by FEC. It is observed in this study that the average number of neoadjuvant chemotherapy cycles needed for maximum tumor response is three (Table 3) . (Table 6 ). (Table  7) . Survival: 5 year OS ( Figure 1 ) and DFS (Figure 2 ) of the patients were 67.92% & 62.21% respectively. Local chest wall recurrence was seen in 2.7% and nodal recurrence in 4% patients. Systemic failures were seen in 21.3% of patients. 
DISCUSSION
With the increased use of screening in developed countries, more number of patients is diagnosed in an early stage. But in many parts of the world where screening is not done routinely and locally advanced breast cancer is a clinical problem here. So any research in this area of locally advanced breast cancer will be fruitful to the community and merits priority. In the present prospective study, we have evaluated the role of Primary Preoperative systemic Anthracycline based chemotherapy in primarily inoperable LABC. Considering the different biology and clinical behaviour of inflammatory breast cancer it was not included in this study. Even though several studies have addressed this issue, in India where LABC is a real problem studies are sparse. Hence through this study we have tried to assess the response of two commonly used Anthracycline based chemotherapy i.e.; FAC & FEC and also compared the same with the western population.
The efficacy of primary systemic chemotherapy in down staging the disease and making it operable is nearly 94% in this study. A radical MRM with axillary clearance was achieved in 70.4% while simple mastectomy with axillary dissection in 22.5%. Microscopic surgical clearance achieved in 85.9% of cases. . This proves beyond doubt the role of Anthracycline based neoadjuvant chemotherapy in loco regional control of the disease. The high percentage of radically operated patients in this study is one among the highest reported in literature. The objective clinical tumour response rate in our study was 78.9% with complete clinical response of 11.3% and partial response of 67.6%. As per literature there is large variability and heterogeneity regarding the response rate. But approximately 10-20% of patients get complete clinical response and 50-60% achieves a partial response. [24] [25] [26] [27] [28] [29] [30] Thus it proves beyond doubt the role of Anthracycline combination schedule in Indian women in tumour response.
The complete pathological response rate in this study was 8.0% whereas in several RCT in western population it ranges from 3.7% to 30%. It is observed in our study that those patients who achieved p CR have superior overall survival when compared to other patients (100% Vs 65.5%) who have not achieved it. In Taxanes based study like NSABP-27 the pCR improved significantly to 26.1%. Complete clinical nodal response rate was 46.9% & complete pathological nodal response rate was 39.4% in this study.
The toxicity profile of our study was the same as in other studies. Both FAC &FEC schedules are well tolerated. There was no significant short or long term toxicity attributable to chemotherapy.
In this study it is observed that more than 95% of patients have tumour Grade 2 or 3. Nearly 57% are Endocrine unresponsive (both ER/PR -Ve). When receptor status is compared to western population it is seen that our study group has significantly lower receptor positivity. All these biological factors point out the fact that the tumour will be more aggressive in Indian population when compared to white. In this clinical scenario newer combination schedules must be explored to overcome the aggressiveness. Since majority of Indian patients present at a very advanced stage screening must be incorporated in health programmes for early detection.
With regard to down staging of the disease and thereby achieving better local control of the disease, FAC/FEC schedule is a good option. But the p CR rates and survival outcomes of these patients are not satisfactory. The five year Overall survival was 67.92% and Disease free survival was 62.21%. The five year Overall survival as per the literature varies widely. The survival in this cohort of patients is good compared to several other studies.
Among the patients who failed majority were systemic failures, thereby pointing to the fact that this regimen is inadequate in controlling metastases. Hence newer combination schedules incorporating agents like taxanes are needed, at least in the postoperative adjuvant setting in LABC patients. So new research works addressing these issues especially in Indian setting is essential. We have also completed another study addressing the addition of taxanes in LABC patients.
Our study has limitations. It is not an RCT and only an observational study of the patients who are reporting to the department for routine treatment for LABC.
CONCLUSION
PST with Anthracycline combination agents is a reasonable standard treatment for locally advanced breast cancer in Indian population as well. It contributes to high operability of primarily inoperable LABC and even breast conserving surgery become feasible in a sizeable number of patients. Considering the aggressiveness shown by the poor endocrine responsiveness among Indian population more randomized controlled trials are warranted in this area. Breast cancer awareness and screening programmes including mammography must gain importance in Indian population and such widespread programs may bring out a revolution in early detection.
